Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.

British Journal of Haematology
Alex BatallerGrupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM)

Abstract

In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81·5% and 82%, respectively. Forty-six patients required additional therapy for MF (n = 33) or haematological relapse (HemR; n = 13), resulting in a molecular LFS (molLFS) and a cumulative incidence of MF at two years of 61% and 38% respectively. Two-year OS for these 46 patients was 66%, with a different outcome between patients with MF (86%) and HemR (42%) (P = 0·002). Quantitative NPM1 detection at different timepoints was predictive of molLFS; an MRD ratio (NPM1mut/ABL1 × 100) cut-off of 0·05 after first consolidation identified two cohorts with a two-year ...Continue Reading

References

Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Feb 5, 2013·Blood·Marta PratcoronaUNKNOWN Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas
May 25, 2013·Blood·Jan KrönkeKonstanze Döhner
Sep 6, 2013·Leukemia & Lymphoma·Preetesh JainFarhad Ravandi
Sep 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenRobert Soiffer
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daisuke ArakiRoland B Walter
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
May 3, 2019·Nature Communications·Sibylle CocciardiKonstanze Döhner

❮ Previous
Next ❯

Citations

Jul 1, 2020·British Journal of Haematology·Maria H Gilleece, Bipin N Savani
Nov 11, 2020·Blood·Brunangelo FaliniMaria Paola Martelli
Feb 13, 2021·Frontiers in Oncology·Lok Lam NgaiJacqueline Cloos
Apr 22, 2021·Leukemia·Brunangelo FaliniMaria Paola Martelli
Sep 14, 2021·Blood Advances·Guadalupe OñateMarta Pratcorona

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Min ZhouShu-Hong Shen
Zhongguo shi yan xue ye xue za zhi
Hua-Ying Chen, Quan-Yi Lu
© 2022 Meta ULC. All rights reserved